Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Apr 20, 2023 2:40pm

136 Views

Post# 35405817

RE:RE:RE:RE:Dr. Chamie Interview - Quilt 3.032 study (N-803 + BCG)

Thanks for that. So 28 out of 82 patients were still CR at 24 months - 34% 7 of those 28 are no longer in the trial (for whatever reason) so they won't know how long they will maintain their CR. 21 CR patients - 26% - will continue being assessed and will presumably continue getting treatments as it is deemed appropriate.

DJDawg wrote:
I feel that this picture tells a better story.

https://twitter.com/NEJMEvidence/status/1608100507368968194/photo/1

Note that the asco poster for TLD-1433 is similar format in some ways except for ASCO they included all the 3 month Non responders whereas the N-803 display just shows the 58 responder.